Skip Nav Destination
            
    
            
 
    
    
        
            
                
                    
                        
                        
                            
                        
                    
                
                    
                    
                        
                    
                
                
                    
                        
                        
                            
                        
                    
            
        
    
    
    
    
        
            
        
        
    
        
    
    
    
 
    
                
                    
            
    
        
    
    
                    
        
        
        CART19 in Hodgkin lymphoma: are we driving the right model?
        
        
            
        
    
        
    
            
                
            
    
    
    
        
        
     
    
                     
    
                     
    
                     
    
                    
        
                    
        
        CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET
        
        
            
        
    
        
                
            
    
    
    
        
                    
        
        Nonviral RNA chimeric antigen receptor–modified T cells in patients with Hodgkin lymphoma
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                     
    
                    
        
                    
                
            
    
    
    
        
                    
                
            
    
    
    
        
        
     
    
                    
        
                    
                
            
    
    
    
        
                    
                
            
    
    
    
        
        
     
    
                    
        
        
     
    
 
    
            
    
        
    
         
 
    
    
        
    
            
    
        
    
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
        
    
    
    
            
        
 
    
    
 
    
    
        
    
    
    
            
        
            
    
        
        
    
             
            
             
            
             
        
    
 
    
    
 
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
 
    
    
    
    
        
    Issue Archive
Table of Contents
BLOOD COMMENTARIES
CLINICAL TRIALS AND OBSERVATIONS
                    
        
        CART19 in Hodgkin lymphoma: are we driving the right model?
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
    
            PLENARY PAPER
PERSPECTIVE
BLOOD SPOTLIGHT
CLINICAL TRIALS AND OBSERVATIONS
        
        CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            David J. Straus,Sin-Ho Jung,Brandelyn Pitcher,Lale Kostakoglu,John C. Grecula,Eric D. Hsi,Heiko Schöder,Leslie L. Popplewell,Julie E. Chang,Craig H. Moskowitz,Nina Wagner-Johnston,John P. Leonard,Jonathan W. Friedberg,Brad S. Kahl,Bruce D. Cheson,Nancy L. Bartlett
            
        
    
            
        
        Nonviral RNA chimeric antigen receptor–modified T cells in patients with Hodgkin lymphoma
        
        
            
        
                    
                        Clinical Trials & Observations
                    
                    
                        Brief Report
                    
        
            
    
        
            Jakub Svoboda,Susan R. Rheingold,Saar I. Gill,Stephan A. Grupp,Simon F. Lacey,Irina Kulikovskaya,Megan M. Suhoski,J. Joseph Melenhorst,Brandon Loudon,Anthony R. Mato,Sunita Dwivedy Nasta,Daniel J. Landsburg,Matthew R. Youngman,Bruce L. Levine,David L. Porter,Carl H. June,Stephen J. Schuster
            
        
    
            HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL
            Sean D. Reiff,Elizabeth M. Muhowski,Daphne Guinn,Amy Lehman,Catherine A. Fabian,Carolyn Cheney,Rose Mantel,Lisa Smith,Amy J. Johnson,Wendy B. Young,Adam R. Johnson,Lichuan Liu,John C. Byrd,Jennifer A. Woyach
            
        
    
            Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92
            Eugenio Morelli,Lavinia Biamonte,Cinzia Federico,Nicola Amodio,Maria Teresa Di Martino,Maria Eugenia Gallo Cantafio,Martina Manzoni,Francesca Scionti,Mehmet Kemal Samur,Annamaria Gullà,Maria Angelica Stamato,Maria Rita Pitari,Daniele Caracciolo,Settimio Sesti,Niels M. Frandsen,Marco Rossi,Antonino Neri,Mariateresa Fulciniti,Nikhil C. Munshi,Pierosandro Tagliaferri,Pierfrancesco Tassone
            
        
    
            THROMBOSIS AND HEMOSTASIS
Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway
            Coline Haxaire,Narine Hakobyan,Tania Pannellini,Camila Carballo,David McIlwain,Tak W. Mak,Scott Rodeo,Suchitra Acharya,Daniel Li,Jackie Szymonifka,Xiangqian Song,Sébastien Monette,Alok Srivastava,Jane E. Salmon,Carl P. Blobel
            
        
    
            von Willebrand factor enhances microvesicle-induced vascular leakage and coagulopathy in mice with traumatic brain injury
            Yingang Wu,Wei Liu,Yuan Zhou,Tristan Hilton,Zilong Zhao,Wei Liu,Min Wang,Jason Yeon,Katie Houck,Perumal Thiagarajan,Fangyi Zhang,Fu-Dong Shi,Xiaoping Wu,Min Li,Jing-fei Dong,Jianning Zhang
            
        
    
            BLOOD WORK
- 
        
            Cover Image
        
        
Cover Image
            Hemophilic arthropathy (HA) is a major cause of disability in hemophilia A patients. The authors show that tumor necrosis factor-α and its upstream regulators, iRhom2 and ADAM17, have a pivotal role in synovitis and bone loss in HA. This is evidenced by osteoclasts (red) resorbing bone (blue). See the article by Haxaire et al on page 1064.
 - PDF Icon Front MatterFront Matter
 - PDF Icon Table of ContentsTable of Contents
 - PDF Icon Back MatterBack Matter
 - PDF Icon Editorial BoardEditorial Board
 
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
                    







